Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04MLE
|
||||
| Former ID |
DIB000819
|
||||
| Drug Name |
GKA-23
|
||||
| Synonyms |
GKA-21; GKA-22; GKA-23; GKA-30; GKA-31; GKA-50; GKA-60; Glucokinase activators (diabetes); Glucokinase activators (diabetes), AstraZeneca
|
||||
| Indication | Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1] | Investigative | [543714] | ||
| Company |
AstraZeneca plc
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
c1c(ccc(n1)NC(=O)c1cc(cc(c1)Oc1cc(cc(c1)F)F)O[C@H](COC)<br />C)C(=O)O
|
||||
| CAS Number |
CAS 480463-02-3
|
||||
| Target and Pathway | |||||
| Target(s) | Glucokinase | Target Info | Activator | [543714] | |
| KEGG Pathway | Glycolysis / Gluconeogenesis | ||||
| Galactose metabolism | |||||
| Starch and sucrose metabolism | |||||
| Amino sugar and nucleotide sugar metabolism | |||||
| Butirosin and neomycin biosynthesis | |||||
| Metabolic pathways | |||||
| Biosynthesis of antibiotics | |||||
| Carbon metabolism | |||||
| Insulin signaling pathway | |||||
| Insulin secretion | |||||
| Prolactin signaling pathway | |||||
| Glucagon signaling pathway | |||||
| Type II diabetes mellitus | |||||
| Maturity onset diabetes of the young | |||||
| Central carbon metabolism in cancer | |||||
| Pathway Interaction Database | FOXA2 and FOXA3 transcription factor networks | ||||
| HIF-1-alpha transcription factor network | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.